INCOME TAX (Details Narrative) - USD ($) |
5 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Jul. 04, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2025 |
Jul. 31, 2025 |
Dec. 31, 2024 |
Jul. 31, 2024 |
|
| Effective tax rate | |||||||
| Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 56,000 | $ (313,000) | $ 56,000 | $ (313,000) | |||
| Deferred Tax Assets, Valuation Allowance | 3,904,000 | 3,800,000 | $ 3,904,000 | $ 3,904,000 | $ 3,800,000 | $ 3,848,000 | |
| Gravitics Inc [Member] | |||||||
| Effective tax rate | 0.00% | 0.00% | |||||
| Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 1,600,000 | $ 1,100,000 | |||||
| Deferred Tax Assets, Valuation Allowance | 6,081,000 | 4,487,000 | 6,081,000 | 4,487,000 | |||
| Net operating loss carryforwards | 23,600,000 | 14,200,000 | 23,600,000 | 14,200,000 | |||
| Research and development tax credits | $ 23,000 | $ 23,000 | $ 23,000 | $ 23,000 | |||
| Income tax description | the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The legislation includes significant corporate tax reforms, including the permanent reinstatement of the ability to deduct domestic research and development expenditures as incurred beginning in fiscal 2025, replacing the previous requirement to capitalize and amortize such expenditures over five years. As part of OBBBA, the law changed such that all the R&D costs that were required to be capitalized from 2022 through 2024 can (1) be 100% deducted in 2025, (2) be 50% deducted in 2025 and 50% deducted in 2026, or (3) be deducted over the remaining years per the original amortization schedule. Foreign R&D expenditures are still required to be capitalized and amortized over a period of fifteen years. The Company did not accelerate deductions related to previously capitalized domestic R&D expenditures and continues to amortize such amounts over their original five-year recovery period. | ||||||